Bigal, Marcelo E.
Rapoport, Alan M.
Silberstein, Stephen D.
Walter, Sarah
Hargreaves, Richard J.
Aycardi, Ernesto
Article History
First Online: 11 October 2018
Compliance with Ethical Standards
:
: No funding was provided for writing this manuscript. At the time of writing, former employees of Teva (Bigal and Aycardi) were no longer working with the sponsor.
: Dr Bigal was a full-time employee of Labrys (Chief Medical Officer) and of Teva (Chief Medical Officer and Chief Scientific Officer) and, as such, received salary and equity from both companies. He was directly involved with the development of fremanezumab at all stages. He is currently at Purdue. Dr Rapoport is a consultant and speaker for Teva Pharmaceuticals and was a consultant to Labrys. He is an author on multiple phase II and phase III publications on the program. Dr Silberstein is a consultant to Teva Pharmaceuticals and was a consultant to Labrys. He is an author on multiple phase II and phase III publications on the program and is the primary investigator on the phase III CM program. Dr Walter was a full-time employee at Labrys (Head of Preclinical Research and Clinical Pharmacology) and supported the transition of the program to Teva. Dr Hargreaves was a consultant to Labrys, was a full-time employee at Merck, and is currently a full-time employee at Celgene. Dr Aycardi was a full-time employee at Teva (Head of Development for Fremanezumab). As such, he received salary and equity compensation from Teva. He is currently at Xenon pharmaceuticals.